Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Initiator Or Facilitator? Gottlieb Reflects On First Year As Head Of US FDA

May 12 2018

• By Michael Cipriano

Scott Gottlieb 1st year highlights — Happy Anniversary, Dr. Gottlieb!

Related Content

REMS Barriers: US FDA Takes 'Foundational Step' To Improve Generic Access

Nov 09 2017

Addiction Recovery Medications' 'Stigma' Needs To Be Eliminated, Gottlieb Says

Oct 26 2017

Alzheimer's Guidance Coming From US FDA, Part Of Broader OND Reform

Sep 14 2017

Crackdown On Bad Regenerative Medicine Could Benefit Gene Therapy

Aug 28 2017

Brands Push Back Against REMS Reform, Call Problem Small With Burdensome Fixes

Jul 19 2017

FDA Exploring Whether Public Shaming Can Stop REMS Abuses

Jul 19 2017

FDA Expanding Opioid REMS To Immediate Release Formulations

Jul 11 2017

FDA Reversal Gives Amicus Renewed Hope For US Oral Fabry Launch

Jul 11 2017

Regenerative Medicines Provisions Of Cures Act A Top Priority For CBER

Jun 09 2017

US FDA Offers Sponsors More Attention For Sharing Complex Innovative Trial Designs

Apr 04 2018

Biosimilars Need Better Reimbursement, Not 'Kabuki' Coverage, Gottlieb Tells Insurers

Mar 08 2018

Alkermes Refuse-To-File Reversal: Is It Really Good News For Anyone?

Apr 18 2018

Opioid Legislation Would Require US FDA Guidance On Non-Opioid Pain Medication Development

Apr 24 2018

Opioid Use Disorder: Is Reduced Usage A Better Endpoint Than Abstinence?

Apr 24 2018

Gottlieb: Real Risk Of Congressional Action If Anti-Competitive Actions Continue

May 04 2018

Trump Drug Pricing Plan Includes Part D Surprises, Challenges PBM Business Model

May 12 2018

Disease-Specific Guidances Reflect US FDA's 'Nimble, Collaborative, Patient-Focused' Approach

Feb 16 2018

US FDA Releases Slew Of Guidances On A Fell Day For Complex Generics

Feb 09 2018

Gottlieb Nomination As US FDA Chief Could Signal Changes To Generic Approval Process

Mar 13 2017

Woodcock, Califf Give Thumbs Up To Certain 21<sup>st</sup> Century Cures Provisions

Dec 15 2016

Special Protocol Assessment Draft Guidance Adds Biosimilars, Not Much Clarity

May 09 2016

Related Companies

Albireo Pharma Inc.

Fortress Biotech Inc.

Endo, Inc.

Intellipharmaceutics International Inc.

Amicus Therapeutics, Inc.

Eli Lilly and Company

TherapeuticsMD Inc.

Additional Topics

United States Leadership FDA Regulation BioPharmaceutical

More from Agency Leadership

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window